Gene Bridges Licenses Recombineering Technology to Chugai Pharmaceutical Co., Ltd.

02-Jun-2009 - Japan

Gene Bridges GmbH announced that Chugai Pharmaceutical Co., Ltd. of Tokyo, Japan has completed the amendment to expand the commercial license agreement existing since 2005 for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology, patented in Japan under the title "Novel DNA cloning Method“, is a method for generating targeting vectors or modifying E. coli chromosomes.

“Red/ET is fast becoming the standard DNA engineering technology used in industry and academia worldwide,” commented Gary Stevens, CEO of Gene Bridges GmbH. “Having recently also licensed Red/ET to Daiichi Sankyo and Takeda we are delighted to be signing this amendment to another leading Japanese Pharmaceutical company, which found the existing license agreement worthwhile expanding.”

Gene Bridges is represented in Japan by the distribution partner Funakoshi.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...